4 resultados
This is a Phase I, FiH, randomized, single blind, placebo-controlled study to assess the safety, tolerability and PK of AZD2693 following SAD administration. The study is being performed at a single study center; additional sites may be included, if appropriate. Details of planned cohorts are as
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. NAFLD includes a spectrum of diseases raging from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma.
The prevalence of NAFLD ranges from 20% in the general population to
Often comorbid with obesity, nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States affecting 75-100 million adults, of which 15-20 million have the more severe variant nonalcoholic steatohepatitis (NASH). Conservative estimates project a doubling